The data show that Regorafenib is equivalent to TAS-102 in metastatic CRC.

Published Date: 08 Mar 2023

A real-world comparison showed similar overall survival in patients with refractory metastatic CRC treated with regorafenib or trifluridine/tipiracil (TAS-102).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Glioblastoma treatment breakthrough shows promise

2.

In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.

3.

Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most

4.

Liver cancer cells under pressure: Compression can spark invasion, drug resistance and altered gene activity

5.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot